In the second part of In Vivo's series on mRNA manufacturing, we look at the technology behind the Moderna and Pfizer/BioNTech COVID-19 vaccines. Experts in the field are working on a variety of improvements that will enable quicker, cheaper, surer development and production of what could turn out to be a wide array of vaccines and therapeutics to be churned out by emerging mRNA platforms.

A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.

Merck’s head of clinical immunology and 2022 Rising Leader Aileen Pangan is empowering researchers to become leaders through a highly tailored and honest approach to mentorship.

Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.